Gabaeron

• Robert W. Mahley

Sources: reporter.nih.gov

• National Institute on Aging

  R44, Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4, R44AG060873, US$948.6k, 2019–2021, Aug 20, 2020

Sources: reporter.nih.gov

• Neuronal APOE4-induced early hippocampal network hyperexcitability in Alzheimer's disease pathogenesis

  Founder, Board or leadership role, Apr 3, 2026

• Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer's disease

  Consulting or advice, Founder, Board or leadership role, Oct 11, 2021

Sources: pubmed.ncbi.nlm.nih.gov